Search

Your search keyword '"Morgan, M. P. G."' showing total 8 results
Start Over Author "Morgan, M. P. G."
8 results on '"Morgan, M. P. G."'

1. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest

Author

Dankiewicz J., Cronberg T., Lilja G., Jakobsen J. C., Levin H., Ullen S., Rylander C., Wise M. P., Oddo M., Cariou A., Belohlavek J., Hovdenes J., Saxena M., Kirkegaard H., Young P. J., Pelosi P., Storm C., Taccone F. S., Joannidis M., Callaway C., Eastwood G. M., Morgan M. P. G., Nordberg P., Erlinge D., Nichol A. D., Chew M. S., Hollenberg J., Thomas M., Bewley J., Sweet K., Grejs A. M., Christensen S., Haenggi M., Levis A., Lundin A., During J., Schmidbauer S., Keeble T. R., Karamasis G. V., Schrag C., Faessler E., Smid O., Otahal M., Maggiorini M., Wendel Garcia P. D., Jaubert P., Cole J. M., Solar M., Borgquist O., Leithner C., Abed-Maillard S., Navarra L., Annborn M., Unden J., Brunetti I., Awad A., McGuigan P., Olsen R. B., Cassina T., Vignon P., Langeland H., Lange T., Friberg H., Nielsen N. Collaborators, Erik Roman Pognuz, Umberto Lucangelo, Giorgio Berlot, Elisabetta Macchini., Dankiewicz, J., Cronberg, T., Lilja, G., Jakobsen, J. C., Levin, H., Ullen, S., Rylander, C., Wise, M. P., Oddo, M., Cariou, A., Belohlavek, J., Hovdenes, J., Saxena, M., Kirkegaard, H., Young, P. J., Pelosi, P., Storm, C., Taccone, F. S., Joannidis, M., Callaway, C., Eastwood, G. M., Morgan, M. P. G., Nordberg, P., Erlinge, D., Nichol, A. D., Chew, M. S., Hollenberg, J., Thomas, M., Bewley, J., Sweet, K., Grejs, A. M., Christensen, S., Haenggi, M., Levis, A., Lundin, A., During, J., Schmidbauer, S., Keeble, T. R., Karamasis, G. V., Schrag, C., Faessler, E., Smid, O., Otahal, M., Maggiorini, M., Wendel Garcia, P. D., Jaubert, P., Cole, J. M., Solar, M., Borgquist, O., Leithner, C., Abed-Maillard, S., Navarra, L., Annborn, M., Unden, J., Brunetti, I., Awad, A., Mcguigan, P., Olsen, R. B., Cassina, T., Vignon, P., Langeland, H., Lange, T., Friberg, H., Collaborators:, Nielsen N., ROMAN-POGNUZ, Erik, Lucangelo, Umberto, Berlot, Giorgio, and Macchini, Elisabetta

Subjects
Male, Fever, Heart disease, medicine.medical_treatment, Coma/etiology, Hypothermia, Kaplan-Meier Estimate, Targeted temperature management, GUIDELINES, Out of hospital cardiac arrest, Body Temperature, law.invention, TARGETED TEMPERATURE MANAGEMENT, Randomized controlled trial, Hypothermia, Induced, law, AMERICAN-HEART-ASSOCIATION, EUROPEAN RESUSCITATION COUNCIL, medicine, Humans, Single-Blind Method, Cardiopulmonary resuscitation, Coma, 610 Medicine & health, Aged, Cardiopulmonary Resuscitation, Female, Middle Aged, Out-of-Hospital Cardiac Arrest, Treatment Outcome, business.industry, Induced, General Medicine, medicine.disease, Out-of-Hospital Cardiac Arrest/complications, Fever/etiology, Clinical research, Hypothermia, Induced/adverse effects, CARDIOPULMONARY-RESUSCITATION, Anesthesia, Cardiopulmonary Resuscitation/methods, medicine.symptom, business, Human
Abstract

Hypothermia or Normothermia after Cardiac ArrestThis trial randomly assigned patients with coma after out-of-hospital cardiac arrest to undergo targeted hypothermia at 33 degrees C or normothermia with treatment of fever. At 6 months, there were no significant between-group differences regarding death or functional outcomes.BackgroundTargeted temperature management is recommended for patients after cardiac arrest, but the supporting evidence is of low certainty.MethodsIn an open-label trial with blinded assessment of outcomes, we randomly assigned 1900 adults with coma who had had an out-of-hospital cardiac arrest of presumed cardiac or unknown cause to undergo targeted hypothermia at 33 degrees C, followed by controlled rewarming, or targeted normothermia with early treatment of fever (body temperature, >= 37.8 degrees C). The primary outcome was death from any cause at 6 months. Secondary outcomes included functional outcome at 6 months as assessed with the modified Rankin scale. Prespecified subgroups were defined according to sex, age, initial cardiac rhythm, time to return of spontaneous circulation, and presence or absence of shock on admission. Prespecified adverse events were pneumonia, sepsis, bleeding, arrhythmia resulting in hemodynamic compromise, and skin complications related to the temperature management device.ResultsA total of 1850 patients were evaluated for the primary outcome. At 6 months, 465 of 925 patients (50%) in the hypothermia group had died, as compared with 446 of 925 (48%) in the normothermia group (relative risk with hypothermia, 1.04; 95% confidence interval [CI], 0.94 to 1.14; P=0.37). Of the 1747 patients in whom the functional outcome was assessed, 488 of 881 (55%) in the hypothermia group had moderately severe disability or worse (modified Rankin scale score >= 4), as compared with 479 of 866 (55%) in the normothermia group (relative risk with hypothermia, 1.00; 95% CI, 0.92 to 1.09). Outcomes were consistent in the prespecified subgroups. Arrhythmia resulting in hemodynamic compromise was more common in the hypothermia group than in the normothermia group (24% vs. 17%, PConclusionsIn patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not lead to a lower incidence of death by 6 months than targeted normothermia. (Funded by the Swedish Research Council and others; TTM2 ClinicalTrials.gov number, .)

Published
2021
Full Text
View/download PDF

4. Mortality and HRQoL in ICU patients with delirium: Protocol for 1-year follow-up of AID-ICU trial

Author

Mortensen, C, Poulsen, L, Andersen-Ranberg, N, Perner, A, Lange, T, Estrup S, S, Ebdrup, B, Egerod, I, Rasmussen, B, Hastbacka, J, Caballero, J, Citerio, G, Morgan, M, Samuelson, K, Mathiesen, O, Mortensen C. B., Poulsen L. M., Andersen-Ranberg N. C., Perner A., Lange T., Estrup S S., Ebdrup B. H., Egerod I., Rasmussen B. S., Hastbacka J., Caballero J., Citerio G., Morgan M. P. G., Samuelson K., Mathiesen O., Mortensen, C, Poulsen, L, Andersen-Ranberg, N, Perner, A, Lange, T, Estrup S, S, Ebdrup, B, Egerod, I, Rasmussen, B, Hastbacka, J, Caballero, J, Citerio, G, Morgan, M, Samuelson, K, Mathiesen, O, Mortensen C. B., Poulsen L. M., Andersen-Ranberg N. C., Perner A., Lange T., Estrup S S., Ebdrup B. H., Egerod I., Rasmussen B. S., Hastbacka J., Caballero J., Citerio G., Morgan M. P. G., Samuelson K., and Mathiesen O.

Abstract

Background: Intensive care unit (ICU)-acquired delirium is frequent and associated with poor short- and long-term outcomes for patients in ICUs. It therefore constitutes a major healthcare problem. Despite limited evidence, haloperidol is the most frequently used pharmacological intervention against ICU-acquired delirium. Agents intervening against Delirium in the ICU (AID-ICU) is an international, multicentre, randomised, blinded, placebo-controlled trial investigates benefits and harms of treatment with haloperidol in patients with ICU-acquired delirium. The current pre-planned one-year follow-up study of the AID-ICU trial population aims to explore the effects of haloperidol on one-year mortality and health related quality of life (HRQoL). Methods : The AID-ICU trial will include 1000 participants. One-year mortality will be obtained from the trial sites; we will validate the vital status of Danish participants using the Danish National Health Data Registers. Mortality will be analysed by Cox-regression and visualized by Kaplan-Meier curves tested for significance using the log-rank test. We will obtain HRQoL data using the EQ-5D instrument. HRQoL analysis will be performed using a general linear model adjusted for stratification variables. Deceased participants will be designated the worst possible value. Results: We expect to publish results of this study in 2022. Conclusion: We expect that this one-year follow-up study of participants with ICU-acquired delirium allocated to haloperidol vs. placebo will provide important information on the long-term consequences of delirium including the effects of haloperidol. We expect that our results will improve the care of this vulnerable patient group.

Published
2020

5. Agents intervening against delirium in the intensive care unit (AID-ICU) – Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU

Author

Andersen-Ranberg, N, Poulsen, L, Perner, A, Wetterslev, J, Estrup, S, Lange, T, Ebdrup, B, Hästbacka, J, Morgan, M, Citerio, G, Zafrani, L, Caballero, J, Collet, M, Weber, S, Andreasen, A, Bestle, M, Pedersen, H, Hildebrandt, T, Thee, C, Jensen, T, Dey, N, Nielsen, L, Mathiesen, O, Poulsen, L M, Morgan, M P G, Collet, M O, Andreasen, A S, Pedersen, H B S, Jensen, T B, Nielsen, L G, Andersen-Ranberg, N, Poulsen, L, Perner, A, Wetterslev, J, Estrup, S, Lange, T, Ebdrup, B, Hästbacka, J, Morgan, M, Citerio, G, Zafrani, L, Caballero, J, Collet, M, Weber, S, Andreasen, A, Bestle, M, Pedersen, H, Hildebrandt, T, Thee, C, Jensen, T, Dey, N, Nielsen, L, Mathiesen, O, Poulsen, L M, Morgan, M P G, Collet, M O, Andreasen, A S, Pedersen, H B S, Jensen, T B, and Nielsen, L G

Abstract

Background: Delirium among patients in the intensive care unit (ICU) is a common condition associated with increased morbidity and mortality. Haloperidol is the most frequently used pharmacologic intervention, but its use is not supported by firm evidence. Therefore, we are conducting Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU) trial to assess the benefits and harms of haloperidol for the treatment of ICU-acquired delirium. Methods: AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo. Trial participants will receive intravenous 2.5 mg haloperidol three times daily or matching placebo (isotonic saline 0.9%) if they are delirious. If needed, a maximum of 20 mg/daily haloperidol/placebo is given. An escape protocol, not including haloperidol, is part of the trial protocol. The primary outcome is days alive out of the hospital within 90 days post-randomisation. Secondary outcomes are number of days without delirium or coma, serious adverse reactions to haloperidol, usage of escape medication, number of days alive without mechanical ventilation; mortality, health-related quality-of-life and cognitive function at 1-year follow-up. A sample size of 1000 patients is required to detect a 7-day improvement or worsening of the mean days alive out of the hospital, type 1 error risk of 5% and power 90%. Perspective: The AID-ICU trial is based on gold standard methodology applied to a large sample of clinically representative patients and will provide pivotal high-quality data on the benefits and harms of haloperidol for the treatment ICU-acquired delirium.

Published
2019

6. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU

Author

Krag, Mette, Marker, Søren, Perner, Anders, Wetterslev, Jørn, Wise, Matt P, Schefold, Joerg C, Keus, Frederik, Guttormsen, Anne B, Bendel, Stepani, Borthwick, Mark, Lange, Theis, Rasmussen, Bodil S, Siegemund, Martin, Bundgaard, Helle, Elkmann, Thomas, Jensen, Jacob V, Nielsen, Rune D, Liboriussen, Lisbeth, Bestle, Morten H, Elkjær, Jeanie M, Palmqvist, Dorte F, Bäcklund, Minna, Laake, Jon H, Bådstøløkken, Per M, Grönlund, Juha, Breum, Olena, Walli, Akil, Winding, Robert, Iversen, Susanne, Jarnvig, Inge-Lise, White, Jonathan O, Brand, Björn, Madsen, Martin B, Quist, Lars, Thornberg, Klaus J, Møller, Anders, Wiis, Jørgen, Granholm, Anders, Anthon, Carl T, Meyhoff, Tine S, Hjortrup, Peter B, Aagaard, Søren R, Andreasen, Jo B, Sørensen, Christina A, Haure, Pernille, Hauge, Jacob, Hollinger, Alexa, Scheuzger, Jonas, Tuchscherer, Daniel, Vuilliomenet, T, Takala, J, Jakob, S. M., Vang, M. L., Pælestik, K. B., Andersen, K. L. D., van der Horst, I. C. C., Dieperink, W., Fjølner, J., Kjer, C. K. W., Sølling, C, Sølling, C. G., Karttunen, J., Morgan, M. P. G., Sjøbø, B., Engstrøm, J., Agerholm-Larsen, B, Møller, Morten H, Rasmussen, Bodil Steen, Aagaard, Søren Rosborg, Bønding Andreasen, Jo, Ankjær Sørensen, Christina, Christensen, Pernille Haure, Levin, Marianne, Klemmesen Jensen, Käte, Lundberg, Lillian Skov Søndergaard, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Cardiovascular Centre (CVC), and Critical Care

Subjects
Pantoprazole/adverse effects, Male, INTENSIVE-CARE-UNIT, intraveneuze injecties, law.invention, Proton Pump Inhibitors/adverse effects, intensive care afdelingen, 0302 clinical medicine, Randomized controlled trial, law, overlevingsanalyse, Risk Factors, adults, Medicine, maagzweren, Artikkel, Single-Blind Method, 030212 general & internal medicine, 610 Medicine & health, Pantoprazole, enkele blindering, volwassenen, General Medicine, Middle Aged, Intensive care unit, Intensive Care Units, Injections, Intravenous, STRESS-ULCER PROPHYLAXIS, Female, psychosocial stress, Gastrointestinal Hemorrhage, kritieke ziekte, medicine.drug, medicine.medical_specialty, Gastrointestinal bleeding, risicofactoren, Peptic Ulcer, Randomization, bijwerkingen, Gastrointestinal Hemorrhage/epidemiology, Critical Illness, Placebo, Peptic Ulcer/prevention & control, psychosociale stress, PROTON-PUMP INHIBITORS, 03 medical and health sciences, Medisinske Fag: 700 [VDP], Stress, Physiological, Internal medicine, SCORE, Humans, VDP::Medisinske Fag: 700, Aged, gastro-intestinale bloeding, SEPSIS, business.industry, intravenous injections, 030208 emergency & critical care medicine, Proton Pump Inhibitors, pantaprazole, ta3121, medicine.disease, Survival Analysis, Confidence interval, Critical Illness/mortality, Relative risk, adverse effects, business, single-blind methoden, protonpompremmers
Abstract

Background\ud\udProphylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.\udMethods\ud\udIn this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.\udResults\ud\udA total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups.\udConclusions\ud\udAmong adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621. opens in new tab.)

Published
2018
Full Text
View/download PDF

7. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU

Author

Krag, M., Marker, S., Perner, A., Wetterslev, J., Wise, M. P., Schefold, J. C., Keus, F., Guttormsen, A. B., Bendel, S., Borthwick, M., Lange, T., Rasmussen, B. S., Siegemund, M., Bundgaard, H., Elkmann, T., Jensen, J. V., Nielsen, R. D., Liboriussen, L., Bestle, M. H., Elkjær, J. M., Palmqvist, D. F., Backlund, M., Laake, J. H., Badstolokken, P. M., Gronlund, J., Breum, O., Walli, A., Winding, R., Iversen, S., Jarnvig, I. -L., White, J. O., Brand, B., Madsen, M. B., Quist, L., Thornberg, K. J., Møller, A., Wiis, J., Granholm, A., Anthon, C. T., Meyhoff, T. S., Hjortrup, P. B., Aagaard, S. R., Andreasen, J. B., Sorensen, C. A., Haure, P., Hauge, J., Hollinger, A., Scheuzger, J., Tuchscherer, D., Vuilliomenet, T., Takala, J., Jakob, S. M., Vang, M. L., Paelestik, K. B., Andersen, K. L. D., van der Horst, I. C. C., Dieperink, W., Fjolner, J., Kjer, C. K. W., Solling, C., Solling, C. G., Karttunen, J., Morgan, M. P. G., Sjobo, B., Engstrom, J., Agerholm-Larsen, B., Møller, M. H., Krag, M., Marker, S., Perner, A., Wetterslev, J., Wise, M. P., Schefold, J. C., Keus, F., Guttormsen, A. B., Bendel, S., Borthwick, M., Lange, T., Rasmussen, B. S., Siegemund, M., Bundgaard, H., Elkmann, T., Jensen, J. V., Nielsen, R. D., Liboriussen, L., Bestle, M. H., Elkjær, J. M., Palmqvist, D. F., Backlund, M., Laake, J. H., Badstolokken, P. M., Gronlund, J., Breum, O., Walli, A., Winding, R., Iversen, S., Jarnvig, I. -L., White, J. O., Brand, B., Madsen, M. B., Quist, L., Thornberg, K. J., Møller, A., Wiis, J., Granholm, A., Anthon, C. T., Meyhoff, T. S., Hjortrup, P. B., Aagaard, S. R., Andreasen, J. B., Sorensen, C. A., Haure, P., Hauge, J., Hollinger, A., Scheuzger, J., Tuchscherer, D., Vuilliomenet, T., Takala, J., Jakob, S. M., Vang, M. L., Paelestik, K. B., Andersen, K. L. D., van der Horst, I. C. C., Dieperink, W., Fjolner, J., Kjer, C. K. W., Solling, C., Solling, C. G., Karttunen, J., Morgan, M. P. G., Sjobo, B., Engstrom, J., Agerholm-Larsen, B., and Møller, M. H.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results